Comparative Pharmacology
Head-to-head clinical analysis: TRIMIPRAMINE MALEATE versus VIVACTIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRIMIPRAMINE MALEATE versus VIVACTIL.
TRIMIPRAMINE MALEATE vs VIVACTIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits reuptake of norepinephrine and serotonin, with moderate anticholinergic, sedative, and antihistaminergic effects.
Norepinephrine and serotonin reuptake inhibitor; also has anticholinergic and antihistaminergic activity.
25-150 mg orally once daily at bedtime, starting at 25 mg and titrating up by 25 mg every 3-4 days.
10 mg orally twice daily (morning and afternoon) or 10 mg once daily at bedtime; may increase gradually to 60 mg/day in divided doses.
None Documented
None Documented
Terminal elimination half-life: 22–32 hours (mean 24 hours); in elderly or hepatic impairment, may extend to 40–50 hours requiring dose adjustment.
Terminal elimination half-life ranges 18–34 hours (mean ~25 hours); clinical steady-state achieved within 5–7 days.
Renal: ~70% as metabolites (unchanged <5%); fecal: ~30% via biliary excretion.
Primarily renal (approximately 70% as metabolites, <5% unchanged), with the remainder via fecal/biliary elimination.
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant